Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with chronic lymphocytic leukemia

Bendamustine has shown a favorable safety profile when included in chemotherapy regimens for several types of lymphoma, including chronic lymphocytic leukemia (CLL). This study investigated the long-term effect of adding bendamustine to a conditioning regimen on survival, rate of engraftment, immune...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Bone Marrow Transplant
Autors principals: Khouri, IF, Sui, D, Jabbour, EJ, Samuels, BI, Turturro, F, Alatrash, G, Anderlini, P, Ahmed, S, Oran, B, Ciurea, SO, Marin, D, Olson, A, Patel, KK, Popat, UR, Ledesma, C, Kadia, TM, Ferrajoli, A, Burger, JA, Jorgensen, JL, Medeiros, LJ, Bassett, RL, Gulbis, AM
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849052/
https://ncbi.nlm.nih.gov/pubmed/27595282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2016.204
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars